Combination therapy: the future of management for idiopathic pulmonary fibrosis?

Summary Findings from recently published placebo-controlled trials in idiopathic pulmonary fibrosis have established that pirfenidone and nintedanib prevent about 50% of the decline in forced vital capacity typically seen in this disease; future trials are therefore unlikely to use placebo as a cont...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The lancet respiratory medicine 2014-11, Vol.2 (11), p.933-942
Hauptverfasser:	Wuyts, Wim A, MD, Antoniou, Katerina M, Prof, Borensztajn, Keren, PhD, Costabel, Ulrich, Prof, Cottin, Vincent, Prof, Crestani, Bruno, MD PhD, Grutters, Jan C, Prof, Maher, Toby M, PhD, Poletti, Venerino, Prof, Richeldi, Luca, MD, Vancheri, Carlo, MD PhD, Wells, Athol U, Dr
Format:	Artikel
Sprache:	eng
Schlagworte:	Asthma - drug therapy Drug Therapy, Combination Humans Hypertension, Pulmonary - drug therapy Idiopathic Pulmonary Fibrosis - diagnosis Idiopathic Pulmonary Fibrosis - drug therapy Idiopathic Pulmonary Fibrosis - etiology Lung Diseases, Interstitial - diagnosis Lung Diseases, Interstitial - drug therapy Lung Neoplasms - drug therapy Precision Medicine Pulmonary Disease, Chronic Obstructive - drug therapy Pulmonary/Respiratory
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!